A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Objective: To demonstrate the adverse impact of non-medical switching on patient care. Background: Non-medical switching (NMS) is a policy under which insurers or their pharmacy…Does Team-based Outpatient Palliative Care Improve Patient or Care Partner-Centered Outcomes in Parkinson’s Disease and Related Disorders?
Objective: To assess whether outpatient palliative care (PC) improves patient or caregiver-centered outcomes in Parkinson’s disease and related disorders (PDRD) compared to current standards of…Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis
Objective: To characterize the use of inappropriate antipsychotic therapies among residents with Parkinson’s disease psychosis (PDP) in long-term care (LTC) settings in the US. Background:…Medical management of primary hemifacial spasm
Objective: The purpose of this study is to evaluate the effect of various anti-epileptic drugs(AED) in the medical management of HFS in patients who cannot…Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey
Objective: To understand physicians’ barriers in management of movement disorders (MD) with Onabotulinumtoxin-A (OnabotA). Background: OnabotA effectiveness for treating MD is well known. However, from…Effects of Virtual Reality Exercise Program using the Sony PlayStation 2 gaming platform on Balance, Emotion and Quality of Life in Patients with Parkinson’s Disease
Objective: This study was to investigate the effectiveness of a 12-week virtual reality(VR) exercise program designed around low-cost VR device, the Sony PlayStation 2 (PS2) gaming…Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with or without baseline presence of dyskinesia (BPDys). Background: OPC, a…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.